Olymvax Biopharmaceuticals (688319.SH) received the Phase III clinical study summary report for its recombinant Staphylococcus aureus vaccine (E. coli)

Zhitong Finance APP News, Olymvax Biopharmaceuticals (688319.SH) announced that the company recently received the Phase III clinical study summary report for its recombinant Staphylococcus aureus vaccine (E. coli) (referred to as the "recombinant S. aureus vaccine"). The recombinant S. aureus vaccine demonstrates significant and stable protective efficacy in preventing Staphylococcus aureus infections after surgery, can induce rapid and effective specific immune responses, and exhibits a good safety profile. The clear and favorable benefit-risk assessment supports its marketing application for the indication of "prevention of Staphylococcus aureus infections after orthopedic surgery."